{"id":728849,"date":"2023-02-06T08:12:50","date_gmt":"2023-02-06T13:12:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/"},"modified":"2023-02-06T08:12:50","modified_gmt":"2023-02-06T13:12:50","slug":"cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/","title":{"rendered":"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEWARK, Calif., Feb.  06, 2023  (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\">\n            <strong><br \/>\n              <em><br \/>\n                <u>SVB Securities Global Biopharma Conference<\/u><br \/>\n              <\/em><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%\">Date:<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%\">\u00a0<\/td>\n<td style=\"max-width:84%;width:84%;min-width:84%\">Wednesday, February 15<\/td>\n<\/tr>\n<tr>\n<td>Time:<\/td>\n<td>\u00a0<\/td>\n<td>3:40 pm Eastern Time<\/td>\n<\/tr>\n<tr>\n<td>Location:<\/td>\n<td>\u00a0<\/td>\n<td>Virtual<\/td>\n<\/tr>\n<tr>\n<td>Format:<\/td>\n<td>\u00a0<\/td>\n<td>Fireside Chat<\/td>\n<\/tr>\n<tr>\n<td>Webcast:<\/td>\n<td>\u00a0<\/td>\n<td>\n            <a href=\"http:\/\/ir.cymabay.com\/events\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/ir.cymabay.com\/events<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About CymaBay<br \/><\/strong>CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MoqWSzxfaE5-3dOlcLmFAduKm6FMtMf7HADnHdaJCu27027C5tpDFNIEsn11A_YYUsR1QQJGciuxa2KUQsTK8w==\" rel=\"nofollow noopener\" target=\"_blank\">www.cymabay.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=llsucUP-JaNFvqK86CzmomPUvKBJXrRcbt6N77p2IJ1BgPDA4kHLKJodjZVunOt38ShnK8Km1hPJYg11CWKm-Q==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6lnHWSz5V6_vcplUqDbyztW63kDBTpU8RNaNl9sQfVtV9TUzagLfAH364f3sdO9_vD2v9OoM8elNWF7odMc7nc7UDR7QasB5nYgXqRWrYW19PlZrxS6BSoc3EVCwqKuP\" rel=\"nofollow noopener\" target=\"_blank\">Linkedin<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Statements<\/strong><br \/>\n        <br \/>Any statements made in this press release and at the conference referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, and the timing of the release of seladelpar clinical data are forward-looking statements that are subject to risks and uncertainties. Actual outcomes and results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of product development activities; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of product candidates; and the ability to obtain sufficient financing to complete development, regulatory approval and commercialization of product candidates. Additional risks relating to CymaBay are contained in CymaBay&#8217;s filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.<\/p>\n<p align=\"justify\">For additional information about CymaBay visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MoqWSzxfaE5-3dOlcLmFAbmrMhZcbyOpzMUnJc-W5JjIDWi7ky1DFQdqwmF9dQFtCEDNHLvEMNPopiC3NHc46-qqpcvBjDO7gRStW5lBajPh_Yt05xOAqja8EcTBSrGll6sCJb8Cxwm8tlWnLmOlvv6GjswHgvVxoteN-PNEEJ0A3jdeO93xp4k1_e3-w7IbaSvQrecTLS1rgAiEoSLy19NjjjawxtCzgpoZWN7r3uE=\" rel=\"nofollow noopener\" target=\"_blank\">www.cymabay.com<\/a>.<\/p>\n<p>\n        <strong>Public Relations Contact<\/strong><br \/>\n        <strong>:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<strong>\u00a0<\/strong><\/p>\n<p>Glenn Silver<br \/>Lazar-FINN Partners<br \/>(973) 818-8198<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1R6NjZyyqPkyCFXdBXnOSi4uoQEIiUXeI4pdhtjI6n_-65zdsErCPCsRVtEK2lQVrV6tC5S79A1sq_aR5Mj1YgW6S3StKs-LMWXRw086fg9fo1hS2fZaUTQYWiq6WjPQ\" rel=\"nofollow noopener\" target=\"_blank\">Glenn.silver@finnpartners.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong>\n      <\/p>\n<p>Hans Vitzthum<br \/>LifeSci Advisors, LLC<br \/>(617) 430-7578<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=blE18Hgytn5t1aAgQtpze9mtEuQbwOBpnJ6EvA0OwqWMyIvhFYoFKfjpAb0BLgUeqf8TLujI-D3sVct6LEw_53zSAZPOYeeujSqD2u0aDp5bxhySn2qzKbyEyVmzNqg_W9jvDWeFJEVvg2-dFPwhL3Uem87kwd1DxHptdC0VShlDKQpuWH_w9CpJg-6HDU_mTH7B0NhpPGphfSCbEybNPO7fv8l_uOoTeOtvKkjhT1uyLmqn62xbexwYQxbzyeTwR9M2ZLY9RHmiKMlJnMPzyw==\" rel=\"nofollow noopener\" target=\"_blank\">Hans@LifeSciAdvisors.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YmNhMmIzNTktYzExYS00NDlmLTk3N2UtNWQ5OTUwNjkwZWZhLTEwMzkzODk=\/tiny\/CymaBay-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma Conference Date: \u00a0 Wednesday, February 15 Time: \u00a0 3:40 pm Eastern Time Location: \u00a0 Virtual Format: \u00a0 Fireside Chat Webcast: \u00a0 http:\/\/ir.cymabay.com\/events About CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728849","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma Conference Date: \u00a0 Wednesday, February 15 Time: \u00a0 3:40 pm Eastern Time Location: \u00a0 Virtual Format: \u00a0 Fireside Chat Webcast: \u00a0 http:\/\/ir.cymabay.com\/events About CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets &hellip; Continue reading &quot;CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-06T13:12:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-02-06T13:12:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":437,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/\",\"name\":\"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=\",\"datePublished\":\"2023-02-06T13:12:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk","og_description":"NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma Conference Date: \u00a0 Wednesday, February 15 Time: \u00a0 3:40 pm Eastern Time Location: \u00a0 Virtual Format: \u00a0 Fireside Chat Webcast: \u00a0 http:\/\/ir.cymabay.com\/events About CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets &hellip; Continue reading \"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-06T13:12:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference","datePublished":"2023-02-06T13:12:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/"},"wordCount":437,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/","name":"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=","datePublished":"2023-02-06T13:12:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjgwOSM1MzkxNzM5IzIwMjgzMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728849"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728849\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}